Oncotarget:新型免疫疗法药物组合或可有效治疗癌症

2016-07-14 佚名 生物谷

图片来源:medicalxpress.com 近日,刊登于国际杂志Oncotarget上的一项研究论文中,来自梅奥诊所的研究人员通过研究开发了一种新型药物组合,可以增强机体免疫系统精确狙击杀灭癌细胞的能力,这种新型药物组合或许可以在治疗小鼠机体恶性癌症及转移性癌症上具有一定的治疗效应。 研究者Peter Cohen博士表示,在引发大问题前癌细胞通常会在机体中潜伏数月时间,在这期间其通常会

图片来源:medicalxpress.com

近日,刊登于国际杂志Oncotarget上的一项研究论文中,来自梅奥诊所的研究人员通过研究开发了一种新型药物组合,可以增强机体免疫系统精确狙击杀灭癌细胞的能力,这种新型药物组合或许可以在治疗小鼠机体恶性癌症及转移性癌症上具有一定的治疗效应。

研究者Peter Cohen博士表示,在引发大问题前癌细胞通常会在机体中潜伏数月时间,在这期间其通常会使得免疫系统与癌症共存;文章中我们以Toll样受体(TLR)激动剂来模拟侵入性的细菌,检测其“诱骗”免疫系统攻击癌症的能力,由于化疗方法可以增强免疫疗法,随后我们利用10种不同的化疗制剂对成对的TLR激动剂进行了筛查

文章中,研究者对携带高度恶性乳腺癌(4T1)和胰腺癌(Panc02)的小鼠模型进行靶向研究,他们发现,当化疗制剂环磷酰胺同TLR激动剂进行结合时,恶性的4T1 和Panc02癌症就会在两轮疗法后发生大范围的退化;如果小鼠完成了另外5轮巩固性的疗法那么其癌症病情便不会复发,仅仅当TLR激动剂同环磷酰胺结合时才会持久性地根除癌症,而且目前并没有其它化疗制剂的效果可以达到环磷酰胺的效果。研究者还发现,这种结合性药物疗法耐受性较好,相比单独使用TLR激动剂或环磷酰胺而言毒性作用较小。

研究者表示,患癌小鼠机体中的T淋巴细胞免疫反应可以抵御肿瘤,当每周注射TLR激动剂或环磷酰胺疗法后就可以有效抑制小鼠机体癌症的发展,更重要的是,这种疗法制剂并不需要直接注射到肿瘤中,同时其还可以高效抵御肿瘤的转移。如今梅奥诊所的研究者还在继续深入研究,进行FDA批准的临床试验来检测是否恶性癌症患者对这种组合性疗法的反应同患癌小鼠一样。

原始出处

Manrique SZ1, Dominguez AL1, Mirza N1, Spencer CD1, Bradley JM1, Finke JH2, Lee JJ3,4, Pease LR1, Gendler SJ1,3,5, Cohen PA1,5.Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists..Oncotarget.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2007213, encodeId=66bf200e21371, content=<a href='/topic/show?id=5b268e8387b' target=_blank style='color:#2F92EE;'>#药物组合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87838, encryptionId=5b268e8387b, topicName=药物组合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Thu Mar 23 02:42:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795330, encodeId=a8941e9533010, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat May 13 03:42:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619437, encodeId=49da161943ea0, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 16 01:42:00 CST 2016, time=2016-07-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2007213, encodeId=66bf200e21371, content=<a href='/topic/show?id=5b268e8387b' target=_blank style='color:#2F92EE;'>#药物组合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87838, encryptionId=5b268e8387b, topicName=药物组合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Thu Mar 23 02:42:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795330, encodeId=a8941e9533010, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat May 13 03:42:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619437, encodeId=49da161943ea0, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 16 01:42:00 CST 2016, time=2016-07-16, status=1, ipAttribution=)]
    2017-05-13 闆锋旦
  3. [GetPortalCommentsPageByObjectIdResponse(id=2007213, encodeId=66bf200e21371, content=<a href='/topic/show?id=5b268e8387b' target=_blank style='color:#2F92EE;'>#药物组合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87838, encryptionId=5b268e8387b, topicName=药物组合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Thu Mar 23 02:42:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795330, encodeId=a8941e9533010, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat May 13 03:42:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619437, encodeId=49da161943ea0, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 16 01:42:00 CST 2016, time=2016-07-16, status=1, ipAttribution=)]